360 related articles for article (PubMed ID: 35362798)
21. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
22. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
[TBL] [Abstract][Full Text] [Related]
23. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
[TBL] [Abstract][Full Text] [Related]
24. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
25. Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know.
Couvelard A; Cazes A; Cros J
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101795. PubMed ID: 37429760
[TBL] [Abstract][Full Text] [Related]
26. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
27. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms.
Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP
J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558
[TBL] [Abstract][Full Text] [Related]
30. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).
Sorbye H; Baudin E; Borbath I; Caplin M; Chen J; Cwikla JB; Frilling A; Grossman A; Kaltsas G; Scarpa A; Welin S; Garcia-Carbonero R;
Neuroendocrinology; 2019; 108(1):54-62. PubMed ID: 30153658
[TBL] [Abstract][Full Text] [Related]
31. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
[TBL] [Abstract][Full Text] [Related]
33. Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?
Borbon LC; Tran CG; Sherman SK; Ear PH; Chandrasekharan C; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2022 Oct; 29(11):6936-6946. PubMed ID: 35802214
[TBL] [Abstract][Full Text] [Related]
34. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
[TBL] [Abstract][Full Text] [Related]
37. Digital image analysis of Ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms.
Saetiew K; Angkathunyakul N; Hunnangkul S; Pongpaibul A
Ann Diagn Pathol; 2024 Aug; 71():152295. PubMed ID: 38547761
[TBL] [Abstract][Full Text] [Related]
38. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
Ooki A; Osumi H; Fukuda K; Yamaguchi K
Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
[TBL] [Abstract][Full Text] [Related]
39. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Sorbye H; Kong G; Grozinsky-Glasberg S
Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
[TBL] [Abstract][Full Text] [Related]
40. Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.
Merola E; Falconi M; Rinke A; Staettner S; Krendl F; Partelli S; Andreasi V; Gress TM; Pascher A; Arsenic R; Doglioni C; Kaemmerer D; Wiedenmann B; Pavel ME
Am J Surg; 2020 Aug; 220(2):284-289. PubMed ID: 32209239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
